Daisy M. Jonkers

Maastricht, LI, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Irritable bowel syndrome-specific volatile organic compounds in faecal headspace do not associate with classical symptom-based subtypes.

Irritable bowel syndrome-specific volatile organic compounds in faecal headspace do not associate with classical symptom-based subtypes.

Journal: Journal of breath research

Published: April 07, 2025

Investigating the Immunomodulatory Impact of Fecal Bacterial Membrane Vesicles and Their IgA Coating Patterns in Crohn's Disease Patients.

Investigating the Immunomodulatory Impact of Fecal Bacterial Membrane Vesicles and Their IgA Coating Patterns in Crohn's Disease Patients.

Journal: International journal of molecular sciences

Published: October 28, 2024

In vitro mucin degradation and paracellular permeability by fecal water from Crohn's disease patients.

In vitro mucin degradation and paracellular permeability by fecal water from Crohn's disease patients.

Journal: Future microbiology

Published: March 12, 2024

Integrated fecal microbiome-metabolome signatures reflect stress and serotonin metabolism in irritable bowel syndrome.

Integrated fecal microbiome-metabolome signatures reflect stress and serotonin metabolism in irritable bowel syndrome.

Journal: Gut microbes

Published: April 21, 2022

IgG and IgM cooperate in coating of intestinal bacteria in IgA deficiency.

IgG and IgM cooperate in coating of intestinal bacteria in IgA deficiency.

Journal: Nature communications

Published: December 22, 2021

Severe COVID-19 in inflammatory bowel disease patients in a population-based setting.

Severe COVID-19 in inflammatory bowel disease patients in a population-based setting.

Journal: PloS one

Published: June 05, 2021

Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial.

Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial.

Journal: BMJ open

Published: May 05, 2021

Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial.

Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 29, 2019

Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial.

Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial.

Journal: Lancet (London, England)

Published: January 24, 2017

A 20-Year Temporal Change Analysis in Incidence, Presenting Phenotype and Mortality, in the Dutch IBDSL Cohort-Can Diagnostic Factors Explain the Increase in IBD Incidence?

A 20-Year Temporal Change Analysis in Incidence, Presenting Phenotype and Mortality, in the Dutch IBDSL Cohort-Can Diagnostic Factors Explain the Increase in IBD Incidence?

Journal: Journal of Crohn's & colitis

Published: January 13, 2017

Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats.

Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats.

Journal: Gastroenterology

Published: September 12, 2016

The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis.

The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis.

Journal: Alimentary pharmacology & therapeutics

Published: July 09, 2016

Showing 1-12 of 31

Last Updated: 09/26/2026